



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 23-E-023**

Please note that we have provided this information for the period February to April 2023.

### **You asked:**

**1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another Health Board, and if so which one?**

9 patients received their first definitive treatment in the period specified.

**2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:**

- Paclitaxel in combination with a platinum-based compound – 7 patients
- Platinum-based therapy alone (cisplatin or carboplatin) – 11 patients
- Bevacizumab in combination with paclitaxel and carboplatin - <5\* patients
- Olaparib – 13 patients
- Olaparib + Bevacizumab – 6 patients
- Niraparib – 18 patients
- Rucaparib – 5 patients

**3. Does your Health Board participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.**

During the time period specified, SBUHB did not participate in any clinical trials for the treatment of ovarian cancer.

**4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:**

- Olaparib



- Olaparib + Bevacizumab
- Niraparib
- Other treatments

I can confirm that SBUB do not participate in HRD testing.

**5. If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with:**

- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatments

I can confirm that SBUB do not participate in HRD testing.

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

